Crispr Therapeutics (NASDAQ:CRSP) was downgraded by equities research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Friday, BidAskClub reports.
Several other equities research analysts have also weighed in on the company. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $104.00 target price on shares of Crispr Therapeutics in a research report on Tuesday, November 26th. Chardan Capital reissued a “buy” rating and set a $72.50 price target on shares of Crispr Therapeutics in a report on Monday, November 18th. Oppenheimer raised their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a report on Monday, November 25th. TheStreet raised Crispr Therapeutics from a “d” rating to a “c” rating in a report on Monday, October 28th. Finally, Roth Capital raised their price target on Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $69.54.
Shares of NASDAQ CRSP opened at $65.36 on Friday. Crispr Therapeutics has a 1-year low of $22.22 and a 1-year high of $74.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. The business’s fifty day moving average price is $58.93 and its two-hundred day moving average price is $48.44. The firm has a market capitalization of $3.62 billion, a PE ratio of -19.00 and a beta of 3.31.
Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The firm had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Equities research analysts expect that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.
In related news, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total value of $390,000.00. Following the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $390,000. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock worth $3,620,760 over the last three months. Corporate insiders own 21.40% of the company’s stock.
A number of hedge funds have recently made changes to their positions in CRSP. Nikko Asset Management Americas Inc. boosted its stake in Crispr Therapeutics by 48.4% during the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock valued at $113,846,000 after buying an additional 906,006 shares in the last quarter. Orbimed Advisors LLC bought a new position in Crispr Therapeutics during the third quarter valued at about $21,167,000. Price T Rowe Associates Inc. MD boosted its stake in Crispr Therapeutics by 19.6% during the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after buying an additional 121,176 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Crispr Therapeutics by 23.9% during the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after buying an additional 116,540 shares in the last quarter. Finally, Balyasny Asset Management LLC bought a new position in Crispr Therapeutics during the second quarter valued at about $5,165,000. 49.82% of the stock is owned by institutional investors and hedge funds.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: What Are Cryptocurrencies?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.